Nimbus Therapeutics
Data as of .
Company facts
-
Founded
2009
-
Headquarters
United States (Boston, MA)
Latest funding round
- Round
- Private financing
- Date
- Sep 6, 2023
- Amount
- $210M
- Lead investor
- GV, SR One and Atlas Venture (co-leads)
Drug discovery partners
1 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
Eli Lilly Pharma
Research collaboration and license,
$55M in upfront and near-term milestone payments (up to about $1.3B in total)
Drugs on the board
- Zasocitinib (TAK-279, TYK2 inhibitor)
Phase 3 registry
Plaque psoriasis
Recent news
-
Presents mechanistic data on selective SIK2 inhibitors at IMMUNOLOGY2026
-
To present preclinical SIK2 inhibitor data at ECCO
-
Eli Lilly collaboration up to $1.3B for oral obesity drug
-
Research collaboration and license agreement with Lilly for an oral obesity treatment
-
Takeda reports Phase 3 wins for zasocitinib, which it bought from Nimbus
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.